おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
OriginCell
company
About
OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions.
- 1 - 10
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- ¥410M
- Industries
- Biopharma,Biotechnology,Medical,Medical Device
- Founded date
- Jan 1, 2014
- Number Of Employee
- 1 - 10
- Operating Status
- Active
OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments.OriginCell was founded in 2014 and is headquartered in Shanghai, China.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
¥410M
OriginCell has raised a total of
¥410M
in funding over 2 rounds. Their latest funding was raised on
May 30, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 30, 2022 | Series A | ¥410M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
OriginCell is funded by 1 investors.
Shanghai Gui Guo Assets Management Partnership
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
